Company profile
Neuphoria Therapeutics Inc.
NASDAQ: NEUP · Healthcare · Biotechnology
PublicHQ Burlington, CIK 0001191070Reports USD
#583 of 1,422 Healthcare companies by revenue
EA Score
44DFH 69DQ 11GM —SS 30
v0.1 · 55/100 weight · provisional
↑ return on assets, return on equity · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
-$10.5M
Rev growth YoY (TTM)
-140.7%
Net income (FY)
-$369.6k
Employees
8
as of 2026-08-21
Market cap
$21.3M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$15.6M$15.6M2025
Net income-$369.6k-$369.6k2025
Operating income-$1.1M-$1.1M2025
Total assets$28.6M$28.6M2025
Liabilities$9.6M$9.6M2025
Equity$19.0M$19.0M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Neuphoria Therapeutics Inc.’s revenue?
Neuphoria Therapeutics Inc. booked $15.6M in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -2.4% net margin.
Peers · Healthcare
Profound Medical Corp.44DPatient Portal Technologies, Inc.——Green Growth Brands Inc.——Relay Therapeutics, Inc.57CAllurion Technologies Inc.26DVSee Health, Inc.35DKey facts
CEOSpyridon Papapetropoulos
SectorHealthcare
IndustryBiotechnology
HeadquartersBurlington, null
ExchangeNASDAQ: NEUP
Employees8
IPO date2021-12-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.